These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the healthcare sector.

AbbVie Inc. ABBV

• Dividend Yield: 4.06%
• Mizuho analyst Vamil Divan maintained a Buy rating and raised the price target from $154 to $166 on Feb. 4, 2022. This analyst has an accuracy rate of 71%.
• Jefferies analyst Jeffrey Holford maintained a Buy rating and boosted the price target from $94 to $107 on Sept. 15, 2017. This analyst has an accuracy rate of 69%.
• Recent News: AbbVie’s CEO recently highlighted the loss of exclusivity for its anti-inflammatory drug Humira.

Pfizer Inc. PFE

• Dividend Yield: 3.76%
• DZ Bank analyst Elmar Kraus upgraded the stock from Hold to Buy with a price target of $41 on Feb. 4, 2021. This analyst has an accuracy rate of 72%.
• Goldman Sachs analyst Chris Shibutani upgraded the stock from Neutral to Buy and raised the price target from $47 to $60 on Dec. 13, 2022. This analyst has an accuracy rate of 69%.
• Recent News: Pfizer CEO Albert Bourla recently rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid. The company is scheduled to release quarterly earnings on Jan. 31, 2023.

Gilead Sciences, Inc. GILD

• Dividend Yield: 3.49%
• Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating and raised the price target from $84 to $86 on Oct. 20, 2020. This analyst has an accuracy rate of 76%.
• DZ Bank analyst Elmar Kraus upgraded the stock from Hold to Buy on March 18, 2020. This analyst has an accuracy rate of 72%.
• Recent News: Gilead and EVOQ Therapeutics reported collaboration to advance immunotherapies.

Read More: Investor Optimism Declines Ahead Of Fed's Rate Decision